Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
IRRAS has commercialized its lead product IRRAflow®, a patented intracranial fluid management system that actively irrigates and drains cerebrospinal fluid while continuously monitoring intracranial pressure. The system aims to reduce catheter blockages and infection rates compared to legacy passive systems. The company also markets the Hummingbird line of ICP monitors. In Q4 2022, IRRAS entered into a commercial partnership with Medtronic for US sales of its products. The latest generation of the control unit received FDA clearance in late 2022. Revenue was SEK ~40 million in FY2022; the company remains loss-making but continues to expand commercialization efforts.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on IRRAS.